Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study

2005; Oxford University Press; Volume: 20; Issue: 9 Linguagem: Inglês

10.1093/humrep/dei104

1460-2350

I.A. Araujo Penna, Paulo Roberto Bastos Canella, Rosana Maria dos Reis, Marcos Felipe Silva de Sá, Rui Alberto Ferriani,

Ovarian cancer diagnosis and treatment

BACKGROUND: The present study assessed the effects of low-dose acarbose on obese patients with polycystic ovarian syndrome (PCOS). METHODS: A double-blind placebo-controlled study was conducted on 30 obese hyperinsulinaemic women with PCOS treated with 150 mg/day acarbose or placebo for 6 months. The women were evaluated for hirsutism, menstrual regularity, body mass index (BMI), insulin resistance and glucose tolerance, sex hormone-binding globulin (SHBG), LH, FSH, testosterone and androstenedione, and side-effects. RESULTS: The patients in the acarbose group showed a reduction in BMI (35.87±2.60 versus 33.10±2.94 kg/m2) and in the Ferriman–Gallwey index (8.85±2.31 versus 8±1.82), and an increased chance of menstrual regularity (rate=2.67). SHBG concentration increased (21.01±7.9 versus 23.85±7.77 nmol/l) and the free androgen index was reduced (14.81±9.06 versus 11.48±6.18). None of these parameters were modified in the placebo group. Mild side-effects occurred in 84% of the patients in the acarbose group and disappeared after the first 3 months. CONCLUSION: A low dose of acarbose administered to obese patients with PCOS promotes a reduction in free androgen index and BMI and an increase in SHBG, with improvement of hirsutism and of the menstrual pattern, and is well tolerated by patients.